Literature DB >> 28267533

Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location.

Maxime Ronot1, Francesco Cuccioli2, Marco Dioguardi Burgio2, Marie-Pierre Vullierme2, Olivia Hentic3, Philippe Ruszniewski4, Gaspard d'Assignies2, Valérie Vilgrain5.   

Abstract

PURPOSE: To re-evaluate and compare CT features of neuroendocrine liver metastases (NLM) from pancreatic (p) and enteric (e) gastroenteropancreatic (GEP) tumours.
MATERIAL AND METHODS: From 2006-2013, all patients with proven GEP-neuroendocrine tumours (NETs) with at least one NLM, no previous treatment were included. On unenhanced, arterial and portal phases, NLMs were characterized as hypo-, iso- or hyperattenuating in consensus by 2 radiologists blinded to clinical data. Enhancement patterns (EP) corresponded to the combination of arterial/portal CT attenuation.
RESULTS: 78 patients (43 men, 55%, mean 56±13 yo) and 559NLMs were analyzed. pNLMs were more frequently hypoattenuating on unenhanced CT than eNLMs (72% vs. 57%, p<0.001). 70% of the lesions were hypervascular with no significant difference between pNLMs and eNLMs (p=0.32). eNLMs were more frequently hypoattenuating on portal phase than pNLMs (88% vs. 56%, p<0.001). eNLMs were more frequently hyper/hypo than pNLMs (56% vs. 28%, p<0.001). pNLMs were more frequently hyper/iso than eNLMs (33% vs. 8%, p<0.001). Other NLMs showed various patterns, including hypo/hypo in 12%.
CONCLUSION: Most NLMs of GEP tumours are hypervascular but the enhancement pattern on multiphasic CT depends on the primary tumour. These differences are helpful when the primary tumour has not been diagnosed.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Enhancement pattern; Gastroenteropancreatic; Hypervascular; Metastasis; Neuroendocrine tumour; Oncology; Primary tumour

Mesh:

Year:  2017        PMID: 28267533     DOI: 10.1016/j.ejrad.2017.02.007

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  8 in total

Review 1.  Hepatic nodules with arterial phase hyperenhancement and washout on enhanced computed tomography/magnetic resonance imaging: how to avoid pitfalls.

Authors:  Mimi Tang; Yin Li; Zhi Lin; Bingqi Shen; Mengqi Huang; Zi-Ping Li; Xuehua Li; Shi-Ting Feng
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 2.  Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.

Authors:  Samuel J Galgano; Ajaykumar C Morani; Dheeraj R Gopireddy; Kedar Sharbidre; David D B Bates; Ajit H Goenka; Hina Arif-Tiwari; Malak Itani; Amir Iravani; Sanaz Javadi; Silvana Faria; Chandana Lall; Emily Bergsland; Sadhna Verma; Isaac R Francis; Daniel M Halperin; Deyali Chatterjee; Priya Bhosale; Motoyo Yano
Journal:  Abdom Radiol (NY)       Date:  2022-03-04

Review 3.  New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.

Authors:  Mohammed Saleh; Priya R Bhosale; Motoyo Yano; Malak Itani; Ahmed K Elsayes; Daniel Halperin; Emily K Bergsland; Ajaykumar C Morani
Journal:  Abdom Radiol (NY)       Date:  2020-10-23

4.  Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings.

Authors:  Basak Gulpinar; Elif Peker; Cigdem Soydal; Mine Araz; Atilla Halil Elhan
Journal:  Br J Radiol       Date:  2020-01-16       Impact factor: 3.039

5.  Retrospective analysis of interventional treatment of hepatic metastasis from gastroenteropancreatic neuroendocrine tumors.

Authors:  Peng Liu; Xu Zhu; Jie Li; Ming Lu; Jiahua Leng; Ying Li; Jiangyuan Yu
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

Review 6.  Neuroendocrine Neoplasms of the Small Bowel and Pancreas.

Authors:  Ashley Kieran Clift; Mark Kidd; Lisa Bodei; Christos Toumpanakis; Richard P Baum; Kjell Oberg; Irvin M Modlin; Andrea Frilling
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 5.135

Review 7.  Are recist criteria adequate in assessing the response to therapy in metastatic NEN?

Authors:  Marie-Pierre Vullierme; Philippe Ruszniewski; Louis de Mestier
Journal:  Rev Endocr Metab Disord       Date:  2021-04-19       Impact factor: 9.306

8.  Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection.

Authors:  Emily A Armstrong; Eliza W Beal; Manisha Shah; Bhavana Konda; Sherif Abdel-Misih; Aslam Ejaz; Mary E Dillhoff; Timothy M Pawlik; Jordan M Cloyd
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.